Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to -$61.4 million.

  • Adma Biologics' Enterprise Value rose 2920.41% to -$61.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.4 million, marking a year-over-year increase of 2920.41%. This contributed to the annual value of -$103.1 million for FY2024, which is 10086.27% down from last year.
  • Per Adma Biologics' latest filing, its Enterprise Value stood at -$61.4 million for Q3 2025, which was up 2920.41% from -$90.3 million recorded in Q2 2025.
  • Adma Biologics' 5-year Enterprise Value high stood at -$34.4 million for Q3 2021, and its period low was -$103.1 million during Q4 2024.
  • Its 5-year average for Enterprise Value is -$65.1 million, with a median of -$62.5 million in 2023.
  • As far as peak fluctuations go, Adma Biologics' Enterprise Value soared by 4233.68% in 2021, and later plummeted by 11257.08% in 2023.
  • Adma Biologics' Enterprise Value (Quarter) stood at -$51.1 million in 2021, then plummeted by 69.36% to -$86.5 million in 2022, then skyrocketed by 40.65% to -$51.4 million in 2023, then crashed by 100.86% to -$103.1 million in 2024, then soared by 40.49% to -$61.4 million in 2025.
  • Its Enterprise Value was -$61.4 million in Q3 2025, compared to -$90.3 million in Q2 2025 and -$71.6 million in Q1 2025.